辅助放疗或观察的少突胶质细胞瘤转录因子网络与预后
基于TCGA分子定义的少突胶质细胞瘤患者(137例,65例接受辅助放疗,72例观察),通过转录因子网络重建和生存建模发现,辅助放疗组中与缺氧相关的转录因子活性特征与更短的无病生存期相关,而观察组中另有一特征与较差无病生存期相关。这些特征可能有助于识别需要强化治疗或早期辅助放疗的患者。
要点
- 辅助放疗组中缺氧相关转录因子活性特征与更短DFS相关(中位45 vs 108个月,P<.001)。
- 观察组中另一转录因子活性特征与较差DFS相关(中位72 vs 143个月,P<.01)。
- 上述特征或可分别识别需治疗强化和需 upfront 辅助放疗的患者。
核心结论
- 在分子定义的少突胶质细胞瘤中,辅助放疗组存在与缺氧相关的转录因子活性特征,与更短的无病生存期相关。
- 观察组中另有一个转录因子活性特征与较差的DFS相关,可能识别从早期辅助放疗获益的患者。
研究设计与样本
- 回顾性分析TCGA 2015年低级别胶质瘤临时数据集中分子定义的少突胶质细胞瘤(IDH突变且1p/19q共缺失)患者。
- 共纳入137例患者,其中65例接受辅助放疗,72例观察。
- 使用R包RTN和RTNsurvival进行转录因子网络重建与分析,并使用biospear、plsRCox、survival包进行弹性网络正则化和生存建模。
主要发现
- 辅助放疗组中,与缺氧相关的转录因子活性特征与更短DFS相关(中位45个月 vs 108个月,P<.001)。
- 观察组中未观察到该风险增加(P=.2)。
- 观察组中,另一转录因子活性特征与较差DFS相关(中位72个月 vs 143个月,P<.01)。
临床怎么用
- 对于分子定义的少突胶质细胞瘤患者,辅助放疗后缺氧相关转录因子活性特征阳性者DFS更短,可考虑治疗强化。
- 观察期间转录因子活性特征提示高进展风险者,可能从早期辅助放疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent international sequencing efforts have allowed for the molecular taxonomy of lower-grade gliomas (LGG). We sought to analyze The Cancer Genome Atlas (TCGA, 2015) gene expression datasets on molecularly defined oligodendrogliomas (IDH-mutated and 1p/19q-codeleted) patients treated with adjuvant radiation or those observed to discover prognostic markers and pathways. METHODS: mRNA expression and clinical information of patients with oligodendroglioma were taken from the TCGA "Brain Lower Grade Glioma" provisional dataset. Transcription factor network reconstruction and analysis were performed using the R packages "RTN" and "RTNsurvival." Elastic net regularization and survival modeling were performed using the "biospear," "plsRCox," "survival" packages. RESULTS: From our cohort of 137 patients, 65 received adjuvant radiation and 72 were observed. In the cohort that received adjuvant radiotherapy, a transcription factor activity signature, that correlated with hypoxia, was associated with shorter disease-free survival (DFS) (median = 45 months vs 108 months, P < .001). This increased risk was not seen in patients who were observed (P = .2). Within the observation cohort, a transcription factor activity signature was generated that was associated with poor DFS (median = 72 months. vs 143 months., P < .01). CONCLUSIONS: We identified a transcription factor activity signature associated with poor prognosis in patients with molecular oligodendroglioma treated with adjuvant radiotherapy. These patients would be potential candidates for treatment intensification. A second signature was generated for patients who were more likely to progress on observation. This potentially identifies a cohort who would benefit from upfront adjuvant radiotherapy.
引用
- So J, Mamatjan Y, Zadeh G, et al. Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis. Neuro Oncol. 2021. PMID: 33367753. doi:10.1093/neuonc/noaa300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。